RhumbLine Advisers
LUMO

RhumbLine Advisers’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

RhumbLine Advisers’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,536
Closed -$79K – 3014
2019
Q1 		$79K Buy
4,536
+49
+1% +$731 ﹤0.01% 2888
2018
Q4 		$61K Buy
4,487
+1,314
+41% +$23.1K ﹤0.01% 2928
2018
Q3 		$68K Sell
3,173
-8
-0.3% -$243 ﹤0.01% 2895
2018
Q2 		$136K Buy
3,181
+305
+11% +$14K ﹤0.01% 2835
2018
Q1 		$188K Buy
2,876
+410
+17% +$29.1K ﹤0.01% 2621
2017
Q4 		$180K Sell
2,466
-348
-12% -$28.8K ﹤0.01% 2662
2017
Q3 		$258K Buy
2,814
+42
+2% +$3.22K ﹤0.01% 2617
2017
Q2 		$183K Sell
2,772
-36
-1% -$4.46K ﹤0.01% 2789
2017
Q1 		$609K Buy
2,808
+91
+3% +$13K ﹤0.01% 2166
2016
Q4 		$251K Buy
2,717
+79
+3% +$8.9K ﹤0.01% 2575
2016
Q3 		$357K Sell
2,638
-739
-22% -$73.4K ﹤0.01% 2390
2016
Q2 		$342K Buy
3,377
+887
+36% +$110K ﹤0.01% 2450
2016
Q1 		$408K Buy
2,490
+9
+0.4% +$1.82K ﹤0.01% 2355
2015
Q4 		$813K Buy
2,481
+81
+3% +$26.4K ﹤0.01% 1940
2015
Q3 		$774K Sell
2,400
-80
-3% -$35.1K ﹤0.01% 1939
2015
Q2 		$988K Buy
2,480
+45
+2% +$19.1K ﹤0.01% 1879
2015
Q1 		$1.2M Buy
2,435
+409
+20% +$158K ﹤0.01% 1744
2014
Q4 		$725K Buy
2,026
+191
+10% +$56.8K ﹤0.01% 2017
2014
Q3 		$354K Sell
1,835
-22
-1% -$4.84K ﹤0.01% 2431
2014
Q2 		$444K Buy
1,857
+171
+10% +$34.8K ﹤0.01% 2351
2014
Q1 		$431K Sell
1,686
-46
-3% -$14.1K ﹤0.01% 2316
2013
Q4 		$343K Hold
1,732
– – ﹤0.01% 2506
2013
Q3 		$293K Buy
1,732
+4
+0.2% +$644 ﹤0.01% 2541
2013
Q2 		$307K Buy
+1,728
New +$245K ﹤0.01% 2621

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

RhumbLine Advisers's LUMO Position: Q2 2019 in Review

RhumbLine Advisers sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2019, closing a stake of 4,536 shares — an estimated $79K sold.

RhumbLine Advisers first reported a position in LUMO in Q2 2013 and held it in 24 quarters. The position peaked at $1.2M in Q1 2015. 68 funds tracked by Wall St. Rank hold LUMO as of Q2 2019.

  • RhumbLine Advisers reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • RhumbLine Advisers sold 4,536 Lumos Pharma, Inc. Common Stock shares in Q2 2019, an estimated $79K.
  • RhumbLine Advisers first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 24 quarters.
  • RhumbLine Advisers's Lumos Pharma, Inc. Common Stock position peaked at $1.2M in Q1 2015.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.